Good Salt Life Expands EPA Registrations and Anticipates New Milestone
Good Salt Life (OTC:NDTP) submitted a "me-too" registration to the U.S. EPA for its hypochlorous acid (HOCl) disinfectant seeking an efficacy claim for Clostridioides difficile (C. diff). If approved, the label expansion would allow marketing to hospitals and healthcare facilities concerned with C. diff infection control. The company cited the U.S. healthcare market exceeding $4 trillion and described partnerships on induction charged spray and air scrubbing technologies to enhance surface and air disinfection. Recent EPA registrations include Dog Gone Odor and PurrGuard. The company is awaiting the EPA decision.
- None.
- None.
ATHENS, GEORGIA / ACCESS Newswire / October 9, 2025 / Good Salt Life, Inc., a wholly owned subsidiary of NDT Pharmaceuticals Inc. (OTC:NDTP) ("NDTP" or the "Company"), today announced significant progress in its expanding portfolio of biosecurity solutions. The Company has submitted a "me-too" registration application to the U.S. Environmental Protection Agency (EPA) for its hypochlorous acid (HOCl) disinfectant, which, if approved, would expand the label to include an efficacy claim for Clostridioides difficile (C. diff) on its label.
C. diff is a major concern in healthcare settings, where it can lead to severe infections, prolonged hospital stays, and even fatalities. As one of the leading causes of healthcare-associated infections, effective disinfection against this pathogen is crucial. The ability to claim efficacy against C. diff, if approval is granted, would reinforce Good Salt Life's commitment to providing hospitals and healthcare facilities with reliable solutions to combat this dangerous bacterium, ultimately safeguarding patient health.
With the U.S. healthcare market estimated to exceed
"We are extremely excited about this important milestone and are eagerly awaiting the EPA's decision, and if approval is granted, it will represent a major milestone," said Bill Spilfogel, Senior Vice President of Regulatory Affairs and spokesperson for Good Salt Life. "Approval of a C. diff efficacy claim would represent a groundbreaking advancement for Good Salt Life, solidifying our mission to enhance biosecurity in critical environments."
Ed Mathias, an Advisory Board Member of NDT Pharmaceuticals and instrumental in the founding of The Carlyle Group, added, "By combining the resources of leading organizations with a shared mission, we are helping healthcare facilities create healthier environments for patients and the professionals who care for them."
Good Salt Life's expanding lineup underscores the company's dedication to providing safe, effective, and environmentally conscious cleaning and disinfection solutions across various industries. With innovative products already making waves, including the newly EPA-registered Dog Gone Odor and PurrGuard, Good Salt Life is poised to lead the charge in biosecurity and animal welfare.
About Good Salt Life, Inc.
Good Salt Life is dedicated to promoting vitality through eco-friendly, nature-derived products that support healthier living environments. With a focus on innovation and sustainability, the company offers safe and effective solutions for home, pet, personal care, and animal health. Through strategic partnerships, including collaborations in the B2B animal health sector, Good Salt Life continues to drive advancements that benefit both people and animals. For more information, visit www.goodsaltlife.com.
About NDT Pharmaceuticals, Inc. (OTC:NDTP)
NDT Pharmaceuticals, Inc. (OTC:NDTP) is a publicly traded company focused on advancing innovative consumer health and wellness solutions. With its recent acquisition of Good Salt Life Inc., NDTP has expanded its strategic direction into sustainable, science-driven products that promote healthier living. The Company is committed to building value through investments in brands that protect people, pets, and the planet while aligning with growing consumer demand for eco-friendly and health-conscious alternatives.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect the Company's current expectations and speak only as of the date of this release. Actual results may differ materially from the Company's current expectations. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements.
Contact:
SOURCE: NDT Pharmaceuticals Inc.
View the original press release on ACCESS Newswire
FAQ
What did Good Salt Life (NDTP) file with the EPA on October 9, 2025?
If the EPA approves NDTP's HOCl C. diff claim, what changes for hospitals?
Does Good Salt Life (NDTP) have other EPA-registered products?
What technologies is NDTP pairing with its HOCl disinfectant?
How large is the U.S. healthcare market cited by Good Salt Life (NDTP)?
What is the timeline for the EPA decision on NDTP's C. diff claim?
